Barclays lowered the firm’s price target on Biogen (BIIB) to $180 from $190 and keeps an Equal Weight rating on the shares post the Q3 report. The company’s launches are “still challenged” with increasing competitive noise, while its emerging pipeline catalysts remain weighted to 2026 and beyond, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue